Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Homo sapiens | tumor protein p53 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | macrophage migration inhibitory factor | 0.019 | 0.3829 | 0.5 |
Brugia malayi | Bm-MIF-1, identical | 0.019 | 0.3829 | 1 |
Loa Loa (eye worm) | macrophage migration inhibitory factor 2 | 0.0081 | 0.0736 | 0.1922 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.006 | 0.0127 | 1 |
Loa Loa (eye worm) | macrophage migration inhibitory factor 2 | 0.0081 | 0.0736 | 0.1922 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.0127 | 0.0332 |
Toxoplasma gondii | macrophage migration inhibitory factor, putative | 0.019 | 0.3829 | 0.5 |
Giardia lamblia | Macrophage migration inhibitory factor | 0.019 | 0.3829 | 0.5 |
Onchocerca volvulus | 0.006 | 0.0127 | 0.5 | |
Echinococcus multilocularis | tumor protein p63 | 0.0408 | 1 | 1 |
Plasmodium vivax | macrophage migration inhibitory factor, putative | 0.019 | 0.3829 | 0.5 |
Loa Loa (eye worm) | macrophage migration inhibitory factor | 0.019 | 0.3829 | 1 |
Leishmania major | macrophage migration inhibitory factor-like protein | 0.019 | 0.3829 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.019 | 0.3829 | 0.5 |
Leishmania major | macrophage migration inhibitory factor-like protein | 0.019 | 0.3829 | 0.5 |
Entamoeba histolytica | macrophage migration inhibitory factor-like protein | 0.019 | 0.3829 | 0.5 |
Trichomonas vaginalis | macrophage migration inhibitory factor, mif, putative | 0.019 | 0.3829 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0053 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 7.0795 uM | PUBCHEM_BIOASSAY: qHTS assay for re-activators of p53 using a Luc reporter. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504709] | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.